Optellum (Oxford, UK) is developing the first software for personalized early diagnosis & treatment of lung cancer, based on Artificial Intelligence & Machine Learning.
We provide 1) a patient management platform for incidental and screen-detected pulmonary nodules, and 2) a Lung Cancer Prediction (LCP) digital biomarker that can be applied as a “rule-in” test to speed-up lung cancer diagnosis for patients who require treatment, or as a “rule-out” test to reduce unnecessary and harmful follow-ups.
We are showcasing a prospective multi-center trial of the LCP digital biomarker (a world-first), led by Oxford University Hospitals with the co-authors of NICE and British Thoracic Society guidelines. Be one of the first to see our solution, and get involved in future trials and validation studies.
http://www.optellum.com